Ferrone S - Search Results

1

Immunotherapy of malignant diseases. Challenges and strategies.

Ko EC, Wang X, Ferrone S. Ko EC, et al. Among authors: ferrone s. Int Arch Allergy Immunol. 2003 Dec;132(4):294-309. doi: 10.1159/000074897. Int Arch Allergy Immunol. 2003. PMID: 14707461 Review.

2

Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.

Mittelman A, Wang X, Matsumoto K, Ferrone S. Mittelman A, et al. Among authors: ferrone s. Hybridoma. 1995 Apr;14(2):175-81. doi: 10.1089/hyb.1995.14.175. Hybridoma. 1995. PMID: 7590776 Review.

3

Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies.

Ferrone S, Kageshita T, Hirai S. Ferrone S, et al. J Dermatol. 1993 Sep;20(9):533-9. doi: 10.1111/j.1346-8138.1993.tb01334.x. J Dermatol. 1993. PMID: 8227707 Clinical Trial.

4

Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library.

Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. Desai SA, et al. Among authors: ferrone s. Cancer Res. 1998 Jun 1;58(11):2417-25. Cancer Res. 1998. PMID: 9622083

5

Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells.

Noronha EJ, Wang X, Desai SA, Kageshita T, Ferrone S. Noronha EJ, et al. Among authors: ferrone s. J Immunol. 1998 Sep 15;161(6):2968-76. J Immunol. 1998. PMID: 9743360

6

HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies.

Burlingham WJ, Jankowska-Gan E, DeVito-Haynes L, Fechner JH Jr, Hogan KT, Claas FH, Mulder A, Wang X, Ferrone S. Burlingham WJ, et al. Among authors: ferrone s. J Immunol. 1998 Dec 15;161(12):6705-14. J Immunol. 1998. PMID: 9862700

7

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

Hicklin DJ, Marincola FM, Ferrone S. Hicklin DJ, et al. Among authors: ferrone s. Mol Med Today. 1999 Apr;5(4):178-86. doi: 10.1016/s1357-4310(99)01451-3. Mol Med Today. 1999. PMID: 10203751 Review.

8

Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.

Reinhold U, Liu L, Lüdtke-Handjery HC, Heuser C, Hombach A, Wang X, Tilgen W, Ferrone S, Abken H. Reinhold U, et al. Among authors: ferrone s. J Invest Dermatol. 1999 May;112(5):744-50. doi: 10.1046/j.1523-1747.1999.00586.x. J Invest Dermatol. 1999. PMID: 10233766 Free article.

9

How much longer will tumour cells fool the immune system?

Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. Ferrone S, et al. Immunol Today. 2000 Feb;21(2):70-2. doi: 10.1016/s0167-5699(99)01569-8. Immunol Today. 2000. PMID: 10712001 No abstract available.

10

Analysis by NMR spectroscopy of the structural homology between the linear and the cyclic peptide recognized by anti-human leukocyte antigen class I monoclonal antibody TP25.99*.

Moy FJ, Desai SA, Wang X, Noronha EJ, Zhou Q, Ferrone S, Powers R. Moy FJ, et al. Among authors: ferrone s. J Biol Chem. 2000 Aug 11;275(32):24679-85. doi: 10.1074/jbc.M003647200. J Biol Chem. 2000. PMID: 10825172 Free article.

Previously, we reported the identification of a cyclic and a linear peptide that inhibits mAb TP25.99 binding to the beta(2)-mu-associated and beta(2)-mu-free HLA class I heavy chains (S. A. Desai, X. Wang, E. J. Noronha, Q. Zhou, V. Rebmann, H. Grosse-Wilde, F. J. Moy, R. …

Previously, we reported the identification of a cyclic and a linear peptide that inhibits mAb TP25.99 binding to the beta(2)-mu-associated a …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

938 results

Search Page

Filters